Table 4.
Univariate and multivariate analysis of factors according to PFS in AGC patients treated with anti-PD-1 drugs in the second-line or posterior therapy.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| ≤65 | 1 (reference) | |||
| >65 | 0.944 (0.492-1.814) | 0.863 | – | – |
| Gender | ||||
| Male | 1 (reference) | |||
| Female | 1.227 (0.629-2.394) | 0.547 | – | – |
| Differentiation | ||||
| Poor | 1 (reference) | |||
| Moderate or well | 0.924 (0.495-1.725) | 0.805 | – | – |
| Location | 0.707 | |||
| Upper | 1 (reference) | |||
| Middle | 1.272 (0.542-2.983) | 0.581 | – | – |
| Low | 1.157 (0.532-2.515) | 0.713 | – | – |
| Others | 1.741 (0.675-4.490) | 0.251 | – | – |
| Metastatic site | ||||
| Peritoneal metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.293 (0.635-2.633) | 0.477 | – | – |
| Liver metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.580 (0.847-2.947) | 0.147 | – | – |
| Lymph node metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.231 (0.661-2.292) | 0.512 | – | – |
| Lung metastasis | ||||
| Negative | 1 (reference) | |||
| Positive | 1.172 (0.558-2.461) | 0.675 | – | – |
| Number of metastatic sites | ||||
| ≤2 | 1 (reference) | 1 (reference) | ||
| ≥3 | 2.762 (1.358-5.618) | 0.004 | 2.751 (1.324-5.714) | 0.007 |
| ECOG PS | ||||
| 0-1 | 1 (reference) | 1 (reference) | ||
| ≥2 | 2.712 (1.048-7.017) | 0.032 | 3.595 (1.348-9.588) | 0.011 |
| First line chemotherapeutic regimen | 0.558 | |||
| Fluorouracil+Platinum | 1 (reference) | |||
| Fluorouracil+Taxanes | 1.007 (0.432-2.351) | 0.987 | – | – |
| Others | 1.434 (0.723-2.846) | 0.302 | – | – |
| Alcohol Consumption | ||||
| Abstinence or low risk | 1 (reference) | |||
| Hazardous or harmful | 0.938 (0.333-2.639) | 0.904 | – | – |
| NLR | ||||
| ≤3.11 | 1 (reference) | 1 (reference) | ||
| >3.11 | 1.883 (1.009-3.514) | 0.044 | 1.639 (0.809-3.319) | 0.170 |
| PLR | ||||
| ≤243.33 | 1 (reference) | 1 (reference) | ||
| >243.33 | 2.716 (1.127-6.543) | 0.020 | 2.682 (1.083-6.639) | 0.033 |
| MLR | ||||
| ≤0.20 | 1 (reference) | |||
| >0.20 | 1.497 (0.712-3.146) | 0.284 | – | – |
| dNLR | ||||
| ≤2.09 | 1 (reference) | 1 (reference) | ||
| >2.09 | 2.168 (1.165-4.035) | 0.012 | 1.268 (0.395-4.073) | 0.690 |
| SII | ||||
| ≤1140.91 | 1 (reference) | 1 (reference) | ||
| >1140.91 | 2.356 (1.070-5.188) | 0.028 | 0.765 (0.215-2.718) | 0.679 |
| LDH | ||||
| ≤250 | 1 (reference) | |||
| >250 | 1.288 (0.663-2.500) | 0.454 | – | – |
| CEA | ||||
| ≤5 | 1 (reference) | |||
| >5 | 1.879 (0.991-3.564) | 0.050 | – | – |
| CA199 | ||||
| ≤27 | 1 (reference) | |||
| >27 | 1.038 (0.562-1.920) | 0.904 | – | – |
| CA724 | ||||
| ≤8.2 | 1 (reference) | |||
| >8.2 | 2.087 (0.919-4.737) | 0.072 | – | – |
| Molecular classification | 0.243 | |||
| HER negative | 1 (reference) | |||
| HER positive | 1.448 (0.336-6.235) | 0.619 | – | – |
| Unknown | 1.705 (0.907-3.207) | 0.098 | – | – |